Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose IN-B001 in healthy subjects
NCT04637919Phase 1Unknown
- Sponsor
- HK inno.N Corporation
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IN-B001 CVA16 vaccine in HIV-associated central nervous system involvement (HAND) (3 arms), sponsored by HK inno.N Corporation. Primary endpoint: Frequency and severity of adverse events of IN-B001. Status: unknown.
02
Drugs
IN-B001 CVA16 vaccine
03
Conditions
HIV-associated central nervous system involvement (HAND)
Beyond the preview
Go deeper on NCT04637919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04637919.